Last reviewed · How we verify
NCT06077981
Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections
NA trial testing Submucous Endoscopic Dissection with hydroxyethylamide in Esophageal Neoplasms in 30 participants. Currently enrolling.
30 December 2024
Quick facts
| Lead sponsor | Instituto do Cancer do Estado de São Paulo |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 19 June 2023 |
| Primary completion | 30 December 2024 |
| Estimated completion | 13 April 2026 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Submucous Endoscopic Dissection with hydroxyethylamide
- Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye)
Conditions studied
- Esophageal Neoplasms — all drugs for Esophageal Neoplasms →
- Endoscopic Mucosal Resection — all drugs for Endoscopic Mucosal Resection →
- Hyaluronic Acid — all drugs for Hyaluronic Acid →
Sponsor
Instituto do Cancer do Estado de São Paulo — full company profile →
Who can join
18 and older, any sex, with Esophageal Neoplasms or Endoscopic Mucosal Resection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, single-center clinical trial that will compare the efficacy of two substances used in the submucosal cushion formation stage of endoscopic submucosal resections of early esophageal malignant neoplasms. Such substances are hyaluronic acid in the form of TS-905 Blue Eyeₒ and hydroxyethylamide (Voluven®).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06077981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Neoplasms
Currently open trials in the same condition.
- NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
- NCT07272382 — Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer · NA · recruiting
- NCT06469944 — Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First · Phase 1, PHASE2 · recruiting
- NCT07035587 — Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity · recruiting
- NCT06445972 — Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · Phase 1, PHASE2 · recruiting
Other Instituto do Cancer do Estado de São Paulo trials
Trials by the same sponsor.
- NCT06887621 — Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk f · Phase 2 · recruiting
- NCT07066046 — Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions · NA · recruiting
- NCT06282354 — Telemedicine for Postoperative Follow-up After Oncological Surgeries · unknown
- NCT05622136 — Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma · Phase 2 · active not recruiting
- NCT05996367 — Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06077981 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto do Cancer do Estado de São Paulo
- Last refreshed: 1 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06077981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing